Drug Trial Radar · NCT05774756
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
143
Actual
Start
Apr 26, 2023
Primary completion
Mar 18, 2025
Study completion Apr 16, 2027
Sponsor
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO will take a daily injection of either setmelanotide or placebo and complete trial assessments for 52 weeks on a therapeutic regimen. A separate sub-study in patients with congenital HO is detailed under NCT06760546.
Conditions
- Hypothalamic Obesity
Interventions
SetmelanotideDrug
Solution for daily subcutaneous injection
PlaceboDrug
Placebo matched to setmelanotide for daily subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic RegimenTime frame: Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
Locations
28 sites in 6 countries. Site status is shown where the registry gives one.
UAN Pediatric Endocrinology
Birmingham, Alabama
Rady Children's Hospital
San Diego, California
Children's Hospital Colorado
Aurora, Colorado
University of Florida
Gainesville, Florida
Ann and Robert H. Lurie Children's Hospital
Chicago, Illinois
University of Iowa Stead Family Department of Pediatrics
Iowa City, Iowa
Boston Children's Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Children's Minnesota
Saint Paul, Minnesota
Icahn School of Medicine at Mount Sinai
New York, New York
Columbia University Irving Medical Center
New York, New York
Ohio State Wexner Medical Center
Columbus, Ohio
Lynn Health Science Institute
Oklahoma City, Oklahoma
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Vanderbilt University School of Medicine
Nashville, Tennessee
Seattle Children's Hospital, Research and Foundation - Center for Integrative Brain Research
Seattle, Washington
Hospital for Sick Children
Toronto, Ontario, Canada
Universitaetsklinikum Hamburg-Eppendorf (UKE) - Ambulanzzentrum des UKE GmbH
Hamburg, Germany
Medicover Neuroendokrinologie
München, Germany
University Children's Hospital, Klinikum Oldenburg
Oldenburg, Germany
Universitaetsklinikum Ulm - Klinik fuer Kinder- und Jugendmedizin
Ulm, Germany
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan
Nagano Children's Hospital
Azumino, Nagano, Japan
Toranomon Hospital
Minato, Tokyo, Japan
Prinses Maxima Center for Pediatric Oncology
Utrecht, Netherlands
Birmingham Women and Children's Hospital NHS Trust
Birmingham, United Kingdom
Hull University Teaching Hospital
Hull, United Kingdom
UCL Great Ormond Street Institute of Child Health
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.